Shanghai-based Abbisko Therapeutics has secured $70 million in a Series C round of financing led by Singaporean state-owned investment firm Temasek, bringing the total capital raised by the Chinese biopharma firm to $140 million.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in